The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
Abstract
Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is the presence of the characteristic Hodgkin Reed-Sternberg (HRS) cells in classical HL and so-called lymphocyte-predominant (LP) cells in nodular lymphocyte-predominant HL. HL is unique among all cancers because malignant cells are greatly outnumbered by reactive cells in the tumor microenvironment and make up only approximately 1% of the tumor. Expression of a variety of cytokines and chemokines by the HRS and LP cells is believed to be the driving force for an abnormal immune response, perpetuated by additional factors secreted by reactive cells in the microenvironment that help maintain the inflammatory milieu. The malignant HRS and LP cells manipulate the microenvironment, permitting them to develop their malignant phenotype fully and evade host immune attack. Gene expression signatures derived from non-neoplastic cells correlate well with response to initial and subsequent therapies, reflecting their functional relevance. Recent biomarker studies have added texture to clinical outcome predictors, and their incorporation into prognostic models may improve our understanding of the biologic correlates of treatment failure. Moreover, recent preclinical and clinical studies have demonstrated that the tumor microenvironment represents a promising therapeutic target, raising hope that novel treatment strategies focused on the interface between malignant and reactive cells will soon emerge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
TAN, P. (2001) · A Clinical Approach to Medicine · doi:10.1142/9789810248178_0024 · Cited by 2,697
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationA Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Self-citationProstaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
MIF Signal Transduction Initiated by Binding to CD74
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., & Bucala, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030286 · Cited by 1,154
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
The biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L. R., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 509
Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
Glaser, S. L., Lin, R. J., Stewart, S. L., Ambinder, R. F., Jarrett, R. F., Brousset, P., Pallesen, G., Gulley, M. L., Khan, G., O'Grady, J., et al. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970207)70:4<375::aid-ijc1>3.0.co;2-t · Cited by 506
The role of cytokines in classical Hodgkin lymphoma
Skinnider, B. F., & Mak, T. W. (2002) · Blood · doi:10.1182/blood-2002-01-0099 · Cited by 505
Kilger, E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1700 · Cited by 483
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Schmitz, R., Hansmann, M.-L., Bohle, V., Martin-Subero, J. I., Hartmann, S., Mechtersheimer, G., Klapper, W., Vater, I., Giefing, M., Gesk, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090528 · Cited by 481
CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis
Truman, L. A., Ford, C. A., Pasikowska, M., Pound, J. D., Wilkinson, S. J., Dumitriu, I. E., Melville, L., Melrose, L. A., Ogden, C. A., Nibbs, R., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162404 · Cited by 473
Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J., Gill, K., Klasa, R., Voss, N., Connors, J. M., & Gascoyne, R. D. (2005) · Blood · doi:10.1182/blood-2005-04-1565 · Cited by 461
Self-citationÁlvaro, T., Lejeune, M., Salvadó, M. T., Bosch, R., García, J. F., Jaén, J., Banham, A. H., Roncador, G., Montalbán, C., & Piris, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1869 · Cited by 450
Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S. A., & Dirnhofer, S. (2008) · Haematologica · doi:10.3324/haematol.11702 · Cited by 412
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Iqbal, J., Weisenburger, D. D., Greiner, T. C., Vose, J. M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., et al. (2010) · Blood · doi:10.1182/blood-2009-06-227579 · Cited by 392
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
Bollard, C. M., Aguilar, L., Straathof, K. C., Gahn, B., Huls, M. H., Rousseau, A., Sixbey, J., Gresik, M. V., Carrum, G., Hudson, M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040890 · Cited by 388
Lamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., Lenze, D., Köchert, K., Bouhlel, M. A., Richter, J., Soler, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2129 · Cited by 376
High Expression of the CC Chemokine TARC in Reed-Sternberg Cells
van den Berg, A., Visser, L., & Poppema, S. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65424-7 · Cited by 367
Brune, V., Tiacci, E., Pfeil, I., Döring, C., Eckerle, S., van Noesel, C. J. M., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080809 · Cited by 360
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα
Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F., & Hay, R. T. (1999) · Oncogene · doi:10.1038/sj.onc.1202893 · Cited by 334
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
Walker, P. R., Saas, P., & Dietrich, P. Y. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4521 · Cited by 327
Juszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K., Abramson, J., Chen, W., Kutok, J. L., Rabinovich, G. A., & Shipp, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706017104 · Cited by 327
Weniger, M. A., Melzner, I., Menz, C. K., Wegener, S., Bucur, A. J., Dorsch, K., Mattfeldt, T., Barth, T. F. E., & Möller, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209151 · Cited by 322
Skinnider, B. F., Elia, A. J., Gascoyne, R. D., Patterson, B., Trumper, L., Kapp, U., & Mak, T. W. (2002) · Blood · doi:10.1182/blood.v99.2.618 · Cited by 288
Self-citationClonal Deleterious Mutations in the Iκbα Gene in the Malignant Cells in Hodgkin's Lymphoma
Jungnickel, B., Staratschek-Jox, A., Bräuninger, A., Spieker, T., Wolf, J., Diehl, V., Hansmann, M.-L., Rajewsky, K., & Küppers, R. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.395 · Cited by 283
Bollard, C. M., Gottschalk, S., Leen, A. M., Weiss, H., Straathof, K. C., Carrum, G., Khalil, M., Wu, M.-F., Huls, M. H., Chang, C.-C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-091280 · Cited by 278
Interleukin 13 Is Secreted by and Stimulates the Growth of Hodgkin and Reed-Sternberg Cells
Kapp, U., Yeh, W.-C., Patterson, B., Elia, A. J., Kägi, D., Ho, A., Hessel, A., Tipsword, M., Williams, A., Mirtsos, C., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1939 · Cited by 276
Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A. (2010) · The Journal of Pathology · doi:10.1002/path.2711 · Cited by 275
Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H.-D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3129 · Cited by 261
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255
Ansell, S. M., Horwitz, S. M., Engert, A., Khan, K. D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8972 · Cited by 251
Chetaille, B., Bertucci, F., Finetti, P., Esterni, B., Stamatoullas, A., Picquenot, J. M., Copin, M. C., Morschhauser, F., Casasnovas, O., Petrella, T., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168096 · Cited by 250
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling
Küppers, R., Klein, U., Schwering, I., Distler, V., Bräuninger, A., Cattoretti, G., Tu, Y., Stolovitzky, G. A., Califano, A., Hansmann, M.-L., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16624 · Cited by 243
Joos, S., Menz, C. K., Wrobel, G., Siebert, R., Gesk, S., Ohl, S., Mechtersheimer, G., Trümper, L., Möller, P., Lichter, P., et al. (2002) · Blood · doi:10.1182/blood.v99.4.1381 · Cited by 238
Chiu, A., Xu, W., He, B., Dillon, S. R., Gross, J. A., Sievers, E., Qiao, X., Santini, P., Hyjek, E., Lee, J.-W., et al. (2007) · Blood · doi:10.1182/blood-2006-04-015958 · Cited by 228
STAT3 is constitutively activated in Hodgkin cell lines
Kube, D., Holtick, U., Vockerodt, M., Ahmadi, T., Haier, B., Behrmann, I., Heinrich, P. C., Diehl, V., & Tesch, H. (2001) · Blood · doi:10.1182/blood.v98.3.762 · Cited by 218
Role of Jak Kinases and STATs in Cytokine Signal Transduction
Leonard, W. J. (2001) · International Journal of Hematology · doi:10.1007/bf02981951 · Cited by 215
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma
Molin, D., Edström, A., Glimelius, I., Glimelius, B., Nilsson, G., Sundström, C., & Enblad, G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03768.x · Cited by 203
Jarrett, R. F., Stark, G. L., White, J., Angus, B., Alexander, F. E., Krajewski, A. S., Freeland, J., Taylor, G. M., Taylor, P. R. A., & for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group (2005) · Blood · doi:10.1182/blood-2004-09-3759 · Cited by 198
Skinnider, B. F. (2001) · Blood · doi:10.1182/blood.v97.1.250 · Cited by 197
von Wasielewski, R., Seth, S., Franklin, J., Fischer, R., Hübner, K., Hansmann, M. L., Diehl, V., & Georgii, A. (2000) · Blood · doi:10.1182/blood.v95.4.1207.004k34_1207_1213 · Cited by 191
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., Young, L. S., & Niedobitek, G. (2009) · Hematological Oncology · doi:10.1002/hon.878 · Cited by 188
Herbst, H., Foss, H., Samol, J., Araujo, I., Klotzbach, H., Krause, H., Agathanggelou, A., Niedobitek, G., & Stein, H. (1996) · Blood · doi:10.1182/blood.v87.7.2918.bloodjournal8772918 · Cited by 187
Karin, M., & Gallagher, E. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00755.x · Cited by 178
Steidl, C., Telenius, A., Shah, S. P., Farinha, P., Barclay, L., Boyle, M., Connors, J. M., Horsman, D. E., & Gascoyne, R. D. (2010) · Blood · doi:10.1182/blood-2009-12-257345 · Cited by 176
Self-citationMerz, H., Houssiau, F., Orscheschek, K., Renauld, J., Fliedner, A., Herin, M., Noel, H., Kadin, M., Mueller-Hermelink, H., & Van Snick, J. (1991) · Blood · doi:10.1182/blood.v78.5.1311.1311 · Cited by 171
Georgakis, G. V., Li, Y., Humphreys, R., Andreeff, M., O'Brien, S., Younes, M., Carbone, A., Albert, V., & Younes, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05656.x · Cited by 171
MicroRNA expression profiling in classic Hodgkin lymphoma
Navarro, A., Gaya, A., Martinez, A., Urbano-Ispizua, A., Pons, A., Balagué, O., Gel, B., Abrisqueta, P., Lopez-Guillermo, A., Artells, R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-096784 · Cited by 170
Circulating clonotypic B cells in classic Hodgkin lymphoma
Jones, R. J., Gocke, C. D., Kasamon, Y. L., Miller, C. B., Perkins, B., Barber, J. P., Vala, M. S., Gerber, J. M., Gellert, L. L., Siedner, M., et al. (2009) · Blood · doi:10.1182/blood-2008-11-189688 · Cited by 170
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma
Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E., et al. (2009) · Blood · doi:10.1182/blood-2009-02-204842 · Cited by 169
Hodgkin’s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Diehl, V., Stein, H., Hummel, M., Zollinger, R., & Connors, J. M. (2003) · Hematology · doi:10.1182/asheducation-2003.1.225 · Cited by 169
Self-citationKurzrock, R., Redman, J. R., Cabanillas, F., JONES, D. M., Rothberg, J. M., & Talpaz, M. (1993) · PubMed · Cited by 168
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M. A., Fiumara, P., Goy, A., Jeha, S., Manning, J. T., Jones, D., et al. (2003) · Cancer · doi:10.1002/cncr.11511 · Cited by 168
Gandhi, M. K., Moll, G., Smith, C., Dua, U., Lambley, E., Ramuz, O., Gill, D., Marlton, P., Seymour, J. F., & Khanna, R. (2007) · Blood · doi:10.1182/blood-2007-01-066100 · Cited by 165
Buglio, D., Georgakis, G. V., Hanabuchi, S., Arima, K., Khaskhely, N. M., Liu, Y.-J., & Younes, A. (2008) · Blood · doi:10.1182/blood-2008-01-133769 · Cited by 161
Diepstra, A., Niens, M., Vellenga, E., van Imhoff, G., Nolte, I., Schaapveld, M., van der Steege, G., van den Berg, A., Kibbelaar, R., te Meerman, G., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66780-3 · Cited by 161
Trümper, L. H. P., Brady, G., Bagg, A., Gray, D. M., Loke, S., Griesser, H., Wagman, R., Braziel, R. M., Gascoyne, R. D., & Vicini, S. (1993) · Blood · doi:10.1182/blood.v81.11.3097.3097 · Cited by 155
Self-citationNiens, M., Jarrett, R. F., Hepkema, B. G., et al. (2007) · Blood · doi:10.1182/blood-2007-05-086934 · Cited by 154
Jundt, F., Anagnostopoulos, I., Bommert, K., Emmerich, F., Müller, G., Foss, H., Royer, H., Stein, H., & Dörken, B. (1999) · Blood · doi:10.1182/blood.v94.6.2065 · Cited by 153
Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A., & Colombatti, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.23119 · Cited by 152
Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells
Emmerich, F., Theurich, S., Hummel, M., Haefker, A., Vry, M. S., Döhner, K., Bommert, K., Stein, H., & Dörken, B. (2003) · The Journal of Pathology · doi:10.1002/path.1454 · Cited by 152
Carbone, A., Gloghini, A., Gruss, H. J., & Pinto, A. (1995) · Europe PMC (PubMed Central) · Cited by 150
Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease
Jücker, M., Abts, H. F., Li, W., Schindler, R., Merz, H., Günther, A., Kalle, C. V., Schaadt, M., Diamantstein, T., & Feller, A. C. (1991) · Blood · doi:10.1182/blood.v77.11.2413.2413 · Cited by 149
Teruya‐Feldstein, J., Jaffe, E. S., Burd, P. R., Kingma, D. W., Setsuda, J., & Tosato, G. (1999) · Blood · doi:10.1182/blood.v93.8.2463.408k02_2463_2470 · Cited by 147
Scheeren, F., Diehl, S., Smit, L., Beaumont, T., Naspetti, M., Bende, R., Blom, B., Karube, K., Ohshima, K., van Noesel, C. V., et al. (2008) · Blood · doi:10.1182/blood-2007-08-105643 · Cited by 146
Sánchez‐Aguilera, A. (2006) · Blood · doi:10.1182/blood-2005-12-5125 · Cited by 143
Rehwald, U., Schulz, H., Reiser, M., Sieber, M., Staak, J. O., Morschhauser, F., Driessen, C., Rüdiger, T., Müller-Hermelink, K., Diehl, V., et al. (2002) · Blood · doi:10.1182/blood.v101.2.420 · Cited by 143
Mottok, A., Renné, C., Willenbrock, K., Hansmann, M., & Bräuninger, A. (2007) · Blood · doi:10.1182/blood-2007-03-082511 · Cited by 142
Mathas, S., Jöhrens, K., Joos, S., Lietz, A., Hummel, F., Janz, M., Jundt, F., Anagnostopoulos, I., Bommert, K., Lichter, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3620 · Cited by 140
Fischer, M., Juremalm, M., Olsson, N., Backlin, C., Sundström, C., Nilsson, K., Enblad, G., & Nilsson, G. P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11370 · Cited by 135
Diepstra, A., Imhoff, G. W. V., Karim‐Kos, H. E., van den Berg, A., Meerman, G. J. T., Niens, M., Nolte, I. M., Bastiaannet, E., Schaapveld, M., Vellenga, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.0917 · Cited by 131
Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines
Fiumara, P. F., Snell, V., Li, Y., Mukhopadhyay, A., Younes, M., Gillenwater, A. M., Cabanillas, F., Aggarwal, B. B., & Younes, A. (2001) · Blood · doi:10.1182/blood.v98.9.2784 · Cited by 130
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma
Renné, C., Willenbrock, K., Küppers, R., Hansmann, M., & Bräuninger, A. (2005) · Blood · doi:10.1182/blood-2004-10-4008 · Cited by 130
Pinto, A., Aldinucci, D., Gloghini, A., Zagonel, V., Degan, M., Improta, S., Juzbasic, S., Todesco, M., Perin, V., Gattei, V., et al. (1996) · Blood · doi:10.1182/blood.v88.9.3299.bloodjournal8893299 · Cited by 129
Nam‐Cha, S. H., Roncador, G., Sánchez-Verde, L., Montes‐Moreno, S., Acevedo, A., Domínguez-Franjo, P., & Piris, M. A. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318165b0d6 · Cited by 129
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
Dotti, G., Savoldo, B., Pulè, M. A., Straathof, K. C. M., Biagi, E., Yvon, E. S., Vigouroux, S., Brenner, M. K., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-08-3337 · Cited by 128
Molin, D. L., Fischer, M., Xiang, Z., Larsson, U., Harvima, I. T., Venge, P., Nilsson, K., Sundström, C., Enblad, G., & Nilsson, G. P. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02977.x · Cited by 127
Ma, Y., Visser, L., Roelofsen, H., de Vries, M., Diepstra, A., Imhoff, G. W. V., van der Wal, T., Luinge, M. A., Álvarez‐Llamas, G., Vos, H. J., et al. (2007) · Blood · doi:10.1182/blood-2007-09-112128 · Cited by 127
Morente, M. M., Piris, M. A., Abraira, V., Acevedo, A., Aguilera, B., Bellas, C., Fraga, M., García-del-Moral, R., Gomez-Marcos, F., Menárguez, J., et al. (1997) · PubMed · doi:10.1182/blood.v90.6.2429 · Cited by 125
Höpken, U. E., Foss, H., Meyer, D., Hinz, M., Leder, K., Stein, H., & Lipp, M. (2002) · Blood · doi:10.1182/blood.v99.4.1109 · Cited by 120
Leonard, J. P., Friedberg, J. W., Younes, A., Fisher, D. C., Gordon, L. I., Moore, J. O., Czuczman, M. S., Miller, T. P., Stiff, P. J., Cheson, B. D., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm114 · Cited by 118
Kelley, T. W., Pohlman, B. L., Elson, P. J., & Hsi, E. D. (2007) · American Journal of Clinical Pathology · doi:10.1309/nb3947k383dj0lq2 · Cited by 116
Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome
Ménétrier‐Caux, C., Gobert, M., & Caux, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1642 · Cited by 111
Weihrauch, M. R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V., Bohlen, H., Wolf, J., & Schultze, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0100 · Cited by 110
Zheng, B., Georgakis, G. V., Li, Y., Bharti, A. C., McConkey, D. J., Aggarwal, B. B., & Younes, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0494 · Cited by 110
Cattaruzza, L., Gloghini, A., Olivo, K., Francia, R. D., Lorenzon, D., Filippi, R. D., Carbone, A., Colombatti, A., Pinto, A., & Aldinucci, D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24389 · Cited by 104
Chemnitz, J. M., Driesen, J., Claßen, S., Riley, J. L., Debey, S., Beyer, M., Popov, A., Zander, T., & Schultze, J. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3252 · Cited by 104
Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., Holash, J. A., Goldbeck, C., Xu, X., Kadel, E. E., Lee, S. H., et al. (2008) · Blood · doi:10.1182/blood-2007-04-084756 · Cited by 103
Immunobiology and Pathophysiology of Hodgkin Lymphomas
Poppema, S. (2005) · Hematology · doi:10.1182/asheducation-2005.1.231 · Cited by 102
Foss, H., Herbst, H., Oelmann, E. M., Samol, J., Grebe, M., Blankenstein, T. J. F., Matthes, J., Qin, Z., Falini, B., Pileri, S. A., et al. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03138.x · Cited by 100
Álvaro-Naranjo, T., Lejeune, M., Salvadó-Usach, T., Bosch, R., Reverter‐Branchat, G., Jaén, J., & Pons, L. E. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500220654 · Cited by 100
Diepstra, A., Imhoff, G. W. V., Schaapveld, M., Karim‐Kos, H. E., van den Berg, A., Vellenga, E., & Poppema, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5138 · Cited by 99
Merz, H., Fliedner, A., Orscheschek, K., Binder, T. M., Sebald, W., Müller-Hermelink, H. K., & Feller, A. C. (1991) · PubMed Central · Cited by 96
Gene expression profiling defines molecular subtypes of classical Hodgkin's disease
Devilard, É., Bertucci, F., Trempat, P., Bouabdallah, R., Loriod, B., Giaconia, A., Brousset, P., Granjeaud, S., Nguyen, C., Birnbaum, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205418 · Cited by 96
Khan, G. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2005.11.008 · Cited by 94
Ohshima, K., Akaiwa, M., Umeshita, R., Suzumiya, J., Izuhara, K., & Kikuchi, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01083.x · Cited by 92
Hanamoto, H., Nakayama, T., Miyazato, H., Takegawa, S., Hieshima, K., Tatsumi, Y., Kanamaru, A., & Yoshie, O. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63187-2 · Cited by 92
Martín-Subero, J. I., Wlodarska, I., Bastard, C., Picquenot, J.-M., Höppner, J., Giefing, M., Klapper, W., & Siebert, R. (2006) · Blood · doi:10.1182/blood-2005-09-3843 · Cited by 90
Asano, N., Oshiro, A., Matsuo, K., Kagami, Y., Ishida, F., Suzuki, R., Kinoshita, T., Shimoyama, Y., Tamaru, J., Yoshino, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5342 · Cited by 88
The Role of Chemokines in Hodgkin's Disease
Teruya‐Feldstein, J., Tosato, G., & Jaffe, E. S. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009087027 · Cited by 87
Maggio, E. M., van den Berg, A., Visser, L., Diepstra, A., Kluiver, J. L., Emmens, R., & Poppema, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10399 · Cited by 86
Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease
Teofili, L., Febo, A. D., Pierconti, F., Maggiano, N., Bendandi, M., Rutella, S., Cingolani, A., Renzo, N. D., Musto, P., Pileri, S. A., et al. (2001) · Blood · doi:10.1182/blood.v97.4.1063 · Cited by 79
HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
Diepstra, A., Poppema, S., Boot, M., Visser, L., Nolte, I. M., Niens, M., Meerman, G. J. T., & van den Berg, A. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01005.x · Cited by 77
Peh, S. C., Kim, L., & Poppema, S. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200107000-00011 · Cited by 72
Ma, Y., Visser, L., Blokzijl, T., Harms, G., Atayar, Ç., Poppema, S., & van den Berg, A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.24 · Cited by 71
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma
Younes, A., Pro, B., & Fayad, L. (2006) · Blood · doi:10.1182/blood-2005-09-3731 · Cited by 69
Warzocha, K., Bienvenu, J., Ribeiro, P., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.391 · Cited by 67
Atayar, Ç., Poppema, S., Blokzijl, T., Harms, G., Boot, M., & van den Berg, A. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62238-9 · Cited by 65
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Younes, A. (2009) · Hematology · doi:10.1182/asheducation-2009.1.507 · Cited by 65
Willenbrock, K., Küppers, R., Renné, C., Brune, V., Eckerle, S., Weidmann, E., Bräuninger, A., & Hansmann, M. (2006) · PubMed · Cited by 63
Correale, P., Vecchio, M. T. D., Placa, M. L., Montagnani, F., Genova, G. D., Savellini, G. G., Terrosi, C., Mannucci, S., Giorgi, G., Francini, G., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815b69c8 · Cited by 56
Serum cytokine levels correlate with clinical parameters in Hodgkin’s disease
Gorschlüter, M., Bohlen, H., Hasenclever, D., Diehl, V., & Tesch, H. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059218 · Cited by 56
Classical Hodgkin lymphoma is associated with frequent gains of 17q
Chui, D. T. Y., Hammond, D. W., Baird, M., Shield, L. A., Jackson, R., & Jarrett, R. F. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10266 · Cited by 55
Alexander, W. S. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043013 · Cited by 52
Vascularization predicts overall survival and risk of transformation in follicular lymphoma
Farinha, P., Kyle, A. H., Minchinton, A. I., Connors, J. M., Karsan, A., & Gascoyne, R. D. (2010) · Haematologica · doi:10.3324/haematol.2009.021766 · Cited by 52
Self-citationFoss, H., Herbst, H., Gottstein, S., Demel, G., Araújo, I., & Stein, H. (1996) · Europe PMC (PubMed Central) · Cited by 51
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Sánchez‐Espiridión, B., Montalbán, C., López, Á., Menárguez, J., Sabín, P., Ruiz-Marcellán, C., López, A., Ramos, R. F., Rodríguez, J., Cánovas, A., et al. (2010) · Blood · doi:10.1182/blood-2010-02-270009 · Cited by 50
Luciani, M., Stoppacciaro, A., Peri, G., Mantovani, A., & Ruco, L. (1998) · Molecular Pathology · doi:10.1136/mp.51.5.273 · Cited by 50
The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma
Khnykin, D., Trøen, G., Berner, J., & Delabie, J. (2006) · Journal of Pathology · doi:10.1002/path.1900 · Cited by 49
Fas Ligand Expression in Hodgkin Lymphoma
Verbeke, C. S., Wenthe, U., Grobholz, R., & Zentgraf, H. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200103000-00014 · Cited by 45
Vu, F., Dianzani, U., Ware, C. F., Mak, T. W., & Gommerman, J. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2284 · Cited by 44
Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders
Schwaller, J., Tobler, A., Niklaus, G., et al. (1995) · Blood · doi:10.1182/blood.v85.8.2182.bloodjournal8582182 · Cited by 42
Cayeux, S., Beverley, P. C. L., Schulz, R. J., & Dörken, B. (1993) · PubMed · Cited by 38
The role of interleukin-3 in classical Hodgkin's disease
Aldinucci, D., Olivo, K., Lorenzon, D., Poletto, D., Gloghini, A., Carbone, A., & Pinto, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400013712 · Cited by 37
Sánchez‐Espiridión, B., Sánchez‐Aguilera, A., Montalbán, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1119 · Cited by 37
Follicular Dendritic Cells in Hodgkin’s Disease
Alavaikko, M. J., Hansmann, M., Nebendahl, C., Parwaresch, M. R., & Lennert, K. (1991) · American Journal of Clinical Pathology · doi:10.1093/ajcp/95.2.194 · Cited by 33
Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines
Pons, E., Uphoff, C. C., & Drexler, H. G. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00071-x · Cited by 32
Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma
Kluiver, J. L., Kok, K., Pfeil, I., de Jong, D., Blokzijl, T., Harms, G., van der Vlies, P., Diepstra, A., Atayar, Ç., Poppema, S., et al. (2006) · Hematological Oncology · doi:10.1002/hon.804 · Cited by 28
Toward a Personalized Treatment of Hodgkin's Disease
DeVita, V. T., & Costa, J. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme0912481 · Cited by 24
Cited by
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Self-citationHodgkin lymphoma: A review and update on recent progress
Shanbhag, S., & Ambinder, R. F. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21438 · Cited by 481
Kuang, Z., Guo, L., & Li, X. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7158 · Cited by 11
Metadata
- Authors
- Steidl, C., Connors, J. M., & Gascoyne, R. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-10
- Volume
- 29
- Issue
- 14
- Pages
- 1812-1826
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168937900
- Cited by
- 374
- References
- 142
- FWCI
- 23.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.